The associations representing the European and British life science industry (AESGP, ABPI, BGMA, BIA, EBE, EFPIA, EUCOPE, EuropaBio, Medicines for Europe, PAGB, Vaccines Europe) have today launched a joint policy document on the potential impact of the United Kingdom’s exit the European Union.
Today, organisations representing the life science industry in the EU and the UK have called for medicines to be a priority in phase 2 of the Article 50 negotiations.